Skip to main content
Top
Published in: Journal of Experimental & Clinical Cancer Research 1/2021

Open Access 01-12-2021 | Breast Cancer | Research

Chemotherapy-triggered changes in stromal compartment drive tumor invasiveness and progression of breast cancer

Authors: Jana Plava, Monika Burikova, Marina Cihova, Lenka Trnkova, Bozena Smolkova, Pavel Babal, Lucia Krivosikova, Pavol Janega, Lucia Rojikova, Slavka Drahosova, Martin Bohac, Lubos Danisovic, Lucia Kucerova, Svetlana Miklikova

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2021

Login to get access

Abstract

Background

Chemotherapy remains a standard treatment option for breast cancer despite its toxic effects to normal tissues. However, the long-lasting effects of chemotherapy on non-malignant cells may influence tumor cell behavior and response to treatment. Here, we have analyzed the effects of doxorubicin (DOX) and paclitaxel (PAC), commonly used chemotherapeutic agents, on the survival and cellular functions of mesenchymal stromal cells (MSC), which comprise an important part of breast tumor microenvironment.

Methods

Chemotherapy-exposed MSC (DOX-MSC, PAC-MSC) were co-cultured with three breast cancer cell (BCC) lines differing in molecular characteristics to study chemotherapy-triggered changes in stromal compartment of the breast tissue and its relevance to tumor progression in vitro and in vivo. Conditioned media from co-cultured cells were used to determine the cytokine content. Mixture of BCC and exposed or unexposed MSC were subcutaneously injected into the immunodeficient SCID/Beige mice to analyze invasion into the surrounding tissue and possible metastases. The same mixtures of cells were applied on the chorioallantoic membrane to study angiogenic potential.

Results

Therapy-educated MSC differed in cytokine production compared to un-exposed MSC and influenced proliferation and secretory phenotype of tumor cells in co-culture. Histochemical tumor xenograft analysis revealed increased invasive potential of tumor cells co-injected with DOX-MSC or PAC-MSC and also the presence of nerve fiber infiltration in tumors. Chemotherapy-exposed MSC have also influenced angiogenic potential in the model of chorioallantoic membrane.

Conclusions

Data presented in this study suggest that neoadjuvant chemotherapy could possibly alter otherwise healthy stroma in breast tissue into a hostile tumor-promoting and metastasis favoring niche. Understanding of the tumor microenvironment and its complex net of signals brings us closer to the ability to recognize the mechanisms that prevent failure of standard therapy and accomplish the curative purpose.
Appendix
Available only for authorised users
Literature
1.
go back to reference Siegel RL, Miller KD, Jemal A. Cancer statistics. 2020. CA: a cancer journal for clinicians. 2020;70(1):7–30. Epub 2020/01/09. Siegel RL, Miller KD, Jemal A. Cancer statistics. 2020. CA: a cancer journal for clinicians. 2020;70(1):7–30. Epub 2020/01/09.
2.
go back to reference Ruhle A, Huber PE, Saffrich R, Lopez Perez R, Nicolay NH. The current understanding of mesenchymal stem cells as potential attenuators of chemotherapy-induced toxicity. International journal of cancer. 2018;143(11):2628–39. Epub 2018/06/23.PubMedCrossRef Ruhle A, Huber PE, Saffrich R, Lopez Perez R, Nicolay NH. The current understanding of mesenchymal stem cells as potential attenuators of chemotherapy-induced toxicity. International journal of cancer. 2018;143(11):2628–39. Epub 2018/06/23.PubMedCrossRef
3.
go back to reference Fu D, Calvo JA, Samson LD. Balancing repair and tolerance of DNA damage caused by alkylating agents. Nature reviews Cancer. 2012;12(2):104–20. Epub 2012/01/13.PubMedPubMedCentralCrossRef Fu D, Calvo JA, Samson LD. Balancing repair and tolerance of DNA damage caused by alkylating agents. Nature reviews Cancer. 2012;12(2):104–20. Epub 2012/01/13.PubMedPubMedCentralCrossRef
4.
go back to reference Abotaleb M, Kubatka P, Caprnda M, Varghese E, Zolakova B, Zubor P, et al. Chemotherapeutic agents for the treatment of metastatic breast cancer: An update. Biomedicine pharmacotherapy = Biomedecine pharmacotherapie. 2018;101:458–77. Epub 2018/03/05.PubMedCrossRef Abotaleb M, Kubatka P, Caprnda M, Varghese E, Zolakova B, Zubor P, et al. Chemotherapeutic agents for the treatment of metastatic breast cancer: An update. Biomedicine pharmacotherapy = Biomedecine pharmacotherapie. 2018;101:458–77. Epub 2018/03/05.PubMedCrossRef
5.
go back to reference Hartmann JT, Lipp HP. Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile. Drug safety. 2006;29(3):209–30. Epub 2006/03/10.PubMedCrossRef Hartmann JT, Lipp HP. Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile. Drug safety. 2006;29(3):209–30. Epub 2006/03/10.PubMedCrossRef
6.
go back to reference Gao Y, Shang Q, Li W, Guo W, Stojadinovic A, Mannion C, et al. Antibiotics for cancer treatment: A double-edged sword. J Cancer. 2020;11(17):5135–49. Epub 2020/08/04.PubMedPubMedCentralCrossRef Gao Y, Shang Q, Li W, Guo W, Stojadinovic A, Mannion C, et al. Antibiotics for cancer treatment: A double-edged sword. J Cancer. 2020;11(17):5135–49. Epub 2020/08/04.PubMedPubMedCentralCrossRef
7.
go back to reference Al-Aamri HM, Ku H, Irving HR, Tucci J, Meehan-Andrews T, Bradley C. Time dependent response of daunorubicin on cytotoxicity, cell cycle and DNA repair in acute lymphoblastic leukaemia. BMC Cancer. 2019;19(1):179. Epub 2019/03/01.PubMedPubMedCentralCrossRef Al-Aamri HM, Ku H, Irving HR, Tucci J, Meehan-Andrews T, Bradley C. Time dependent response of daunorubicin on cytotoxicity, cell cycle and DNA repair in acute lymphoblastic leukaemia. BMC Cancer. 2019;19(1):179. Epub 2019/03/01.PubMedPubMedCentralCrossRef
8.
9.
go back to reference Mehraj U, Dar AH, Wani NA, Mir MA. Tumor microenvironment promotes breast cancer chemoresistance. Cancer Chemother Pharmacol. 2021;87(2):147–58. Epub 2021/01/10.PubMedCrossRef Mehraj U, Dar AH, Wani NA, Mir MA. Tumor microenvironment promotes breast cancer chemoresistance. Cancer Chemother Pharmacol. 2021;87(2):147–58. Epub 2021/01/10.PubMedCrossRef
10.
go back to reference Hirata E, Sahai E. Tumor Microenvironment and Differential Responses to Therapy. Cold Spring Harbor perspectives in medicine. 2017;7(7). Epub 2017/02/19. Hirata E, Sahai E. Tumor Microenvironment and Differential Responses to Therapy. Cold Spring Harbor perspectives in medicine. 2017;7(7). Epub 2017/02/19.
11.
go back to reference Gupta GP, Massague J. Cancer metastasis: building a framework. Cell. 2006;127(4):679–95. Epub 2006/11/18.CrossRefPubMed Gupta GP, Massague J. Cancer metastasis: building a framework. Cell. 2006;127(4):679–95. Epub 2006/11/18.CrossRefPubMed
12.
go back to reference Jobling P, Pundavela J, Oliveira SM, Roselli S, Walker MM, Hondermarck H. Nerve-Cancer Cell Cross-talk: A Novel Promoter of Tumor Progression. Cancer research. 2015;75(9):1777–81. Epub 2015/03/22.PubMedCrossRef Jobling P, Pundavela J, Oliveira SM, Roselli S, Walker MM, Hondermarck H. Nerve-Cancer Cell Cross-talk: A Novel Promoter of Tumor Progression. Cancer research. 2015;75(9):1777–81. Epub 2015/03/22.PubMedCrossRef
14.
go back to reference Magnon C, Hall SJ, Lin J, Xue X, Gerber L, Freedland SJ, et al. Autonomic nerve development contributes to prostate cancer progression. Science. 2013;341(6142):1236361. Epub 2013/07/13.PubMedCrossRef Magnon C, Hall SJ, Lin J, Xue X, Gerber L, Freedland SJ, et al. Autonomic nerve development contributes to prostate cancer progression. Science. 2013;341(6142):1236361. Epub 2013/07/13.PubMedCrossRef
15.
go back to reference Conceicao F, Sousa DM, Paredes J, Lamghari M. Sympathetic activity in breast cancer and metastasis: partners in crime. Bone research. 2021;9(1):9. Epub 2021/02/07.PubMedPubMedCentralCrossRef Conceicao F, Sousa DM, Paredes J, Lamghari M. Sympathetic activity in breast cancer and metastasis: partners in crime. Bone research. 2021;9(1):9. Epub 2021/02/07.PubMedPubMedCentralCrossRef
16.
go back to reference Maffey A, Storini C, Diceglie C, Martelli C, Sironi L, Calzarossa C, et al. Mesenchymal stem cells from tumor microenvironment favour breast cancer stem cell proliferation, cancerogenic and metastatic potential, via ionotropic purinergic signalling. Scientific reports. 2017;7(1):13162. Epub 2017/10/17.PubMedPubMedCentralCrossRef Maffey A, Storini C, Diceglie C, Martelli C, Sironi L, Calzarossa C, et al. Mesenchymal stem cells from tumor microenvironment favour breast cancer stem cell proliferation, cancerogenic and metastatic potential, via ionotropic purinergic signalling. Scientific reports. 2017;7(1):13162. Epub 2017/10/17.PubMedPubMedCentralCrossRef
17.
go back to reference He N, Kong Y, Lei X, Liu Y, Wang J, Xu C, et al. MSCs inhibit tumor progression and enhance radiosensitivity of breast cancer cells by down-regulating Stat3 signaling pathway. Cell death disease. 2018;9(10):1026. Epub 2018/10/10.PubMedPubMedCentralCrossRef He N, Kong Y, Lei X, Liu Y, Wang J, Xu C, et al. MSCs inhibit tumor progression and enhance radiosensitivity of breast cancer cells by down-regulating Stat3 signaling pathway. Cell death disease. 2018;9(10):1026. Epub 2018/10/10.PubMedPubMedCentralCrossRef
18.
go back to reference Hmadcha A, Martin-Montalvo A, Gauthier BR, Soria B, Capilla-Gonzalez V. Therapeutic Potential of Mesenchymal Stem Cells for Cancer Therapy. Front Bioeng Biotechnol. 2020;8:43. Epub 2020/03/03.PubMedPubMedCentralCrossRef Hmadcha A, Martin-Montalvo A, Gauthier BR, Soria B, Capilla-Gonzalez V. Therapeutic Potential of Mesenchymal Stem Cells for Cancer Therapy. Front Bioeng Biotechnol. 2020;8:43. Epub 2020/03/03.PubMedPubMedCentralCrossRef
19.
go back to reference Plava J, Cihova M, Burikova M, Bohac M, Adamkov M, Drahosova S, et al. Permanent Pro-Tumorigenic Shift in Adipose Tissue-Derived Mesenchymal Stromal Cells Induced by Breast Malignancy. Cells. 2020;9(2). Epub 2020/02/26. Plava J, Cihova M, Burikova M, Bohac M, Adamkov M, Drahosova S, et al. Permanent Pro-Tumorigenic Shift in Adipose Tissue-Derived Mesenchymal Stromal Cells Induced by Breast Malignancy. Cells. 2020;9(2). Epub 2020/02/26.
20.
go back to reference Matuskova M, Kozovska Z, Toro L, Durinikova E, Tyciakova S, Cierna Z, et al. Combined enzyme/prodrug treatment by genetically engineered AT-MSC exerts synergy and inhibits growth of MDA-MB-231 induced lung metastases. Journal of experimental clinical cancer research: CR. 2015;34:33. Epub 2015/04/18.PubMedPubMedCentralCrossRef Matuskova M, Kozovska Z, Toro L, Durinikova E, Tyciakova S, Cierna Z, et al. Combined enzyme/prodrug treatment by genetically engineered AT-MSC exerts synergy and inhibits growth of MDA-MB-231 induced lung metastases. Journal of experimental clinical cancer research: CR. 2015;34:33. Epub 2015/04/18.PubMedPubMedCentralCrossRef
21.
go back to reference Debreova M, Csaderova L, Burikova M, Lukacikova L, Kajanova I, Sedlakova O, et al. CAIX Regulates Invadopodia Formation through Both a pH-Dependent Mechanism and Interplay with Actin Regulatory Proteins. International journal of molecular sciences. 2019;20(11). Epub 2019/06/07. Debreova M, Csaderova L, Burikova M, Lukacikova L, Kajanova I, Sedlakova O, et al. CAIX Regulates Invadopodia Formation through Both a pH-Dependent Mechanism and Interplay with Actin Regulatory Proteins. International journal of molecular sciences. 2019;20(11). Epub 2019/06/07.
22.
go back to reference Výboh P, Zeman M, Bilčík B, Šárniková B, Košťál Ľ. Angiogenic Effect of Leptin in the Quail Chorioallantoic Membrane. Acta Veterinaria Brno. 2010;79(1):13–7.CrossRef Výboh P, Zeman M, Bilčík B, Šárniková B, Košťál Ľ. Angiogenic Effect of Leptin in the Quail Chorioallantoic Membrane. Acta Veterinaria Brno. 2010;79(1):13–7.CrossRef
23.
go back to reference Parsons-Wingerter P, Lwai B, Yang MC, Elliott KE, Milaninia A, Redlitz A, et al. A novel assay of angiogenesis in the quail chorioallantoic membrane: stimulation by bFGF and inhibition by angiostatin according to fractal dimension and grid intersection. Microvasc Res. 1998;55(3):201–14. Epub 1998/07/11.PubMedCrossRef Parsons-Wingerter P, Lwai B, Yang MC, Elliott KE, Milaninia A, Redlitz A, et al. A novel assay of angiogenesis in the quail chorioallantoic membrane: stimulation by bFGF and inhibition by angiostatin according to fractal dimension and grid intersection. Microvasc Res. 1998;55(3):201–14. Epub 1998/07/11.PubMedCrossRef
24.
go back to reference Parsons-Wingerter P, Elliott KE, Farr AG, Radhakrishnan K, Clark JI, Sage EH. Generational analysis reveals that TGF-beta1 inhibits the rate of angiogenesis in vivo by selective decrease in the number of new vessels. Microvasc Res. 2000;59(2):221–32. Epub 2000/02/24. Parsons-Wingerter P, Elliott KE, Farr AG, Radhakrishnan K, Clark JI, Sage EH. Generational analysis reveals that TGF-beta1 inhibits the rate of angiogenesis in vivo by selective decrease in the number of new vessels. Microvasc Res. 2000;59(2):221–32. Epub 2000/02/24.
25.
go back to reference Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic acids research. 2002;30(9):e36. Epub 2002/04/25.PubMedPubMedCentralCrossRef Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic acids research. 2002;30(9):e36. Epub 2002/04/25.PubMedPubMedCentralCrossRef
26.
go back to reference Angus L, Smid M, Wilting SM, van Riet J, Van Hoeck A, Nguyen L, et al. The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies. Nat Genet. 2019;51(10):1450–8. Epub 2019/10/02.PubMedPubMedCentralCrossRef Angus L, Smid M, Wilting SM, van Riet J, Van Hoeck A, Nguyen L, et al. The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies. Nat Genet. 2019;51(10):1450–8. Epub 2019/10/02.PubMedPubMedCentralCrossRef
27.
go back to reference Karagiannis GS, Pastoriza JM, Wang Y, Harney AS, Entenberg D, Pignatelli J, et al. Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism. Science translational medicine. 2017;9(397). Epub 2017/07/07. Karagiannis GS, Pastoriza JM, Wang Y, Harney AS, Entenberg D, Pignatelli J, et al. Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism. Science translational medicine. 2017;9(397). Epub 2017/07/07.
28.
go back to reference Nwabo Kamdje AH, Kamga PT, Simo RT, Vecchio L, Seke Etet PF, Muller JM, et al. Mesenchymal stromal cells’ role in tumor microenvironment: involvement of signaling pathways. Cancer biology medicine. 2017;14(2):129–41. Epub 2017/06/14.PubMedPubMedCentralCrossRef Nwabo Kamdje AH, Kamga PT, Simo RT, Vecchio L, Seke Etet PF, Muller JM, et al. Mesenchymal stromal cells’ role in tumor microenvironment: involvement of signaling pathways. Cancer biology medicine. 2017;14(2):129–41. Epub 2017/06/14.PubMedPubMedCentralCrossRef
29.
go back to reference Baxter-Holland M, Dass CR. Doxorubicin, mesenchymal stem cell toxicity and antitumour activity: implications for clinical use. The Journal of pharmacy pharmacology. 2018;70(3):320–7. Epub 2018/01/23.PubMedCrossRef Baxter-Holland M, Dass CR. Doxorubicin, mesenchymal stem cell toxicity and antitumour activity: implications for clinical use. The Journal of pharmacy pharmacology. 2018;70(3):320–7. Epub 2018/01/23.PubMedCrossRef
30.
go back to reference Chen DR, Lu DY, Lin HY, Yeh WL. Mesenchymal stem cell-induced doxorubicin resistance in triple negative breast cancer. BioMed research international. 2014;2014:532161. Epub 2014/08/21.PubMedPubMedCentral Chen DR, Lu DY, Lin HY, Yeh WL. Mesenchymal stem cell-induced doxorubicin resistance in triple negative breast cancer. BioMed research international. 2014;2014:532161. Epub 2014/08/21.PubMedPubMedCentral
31.
go back to reference Li J, Law HK, Lau YL, Chan GC. Differential damage and recovery of human mesenchymal stem cells after exposure to chemotherapeutic agents. Br J Haematol. 2004;127(3):326–34. Epub 2004/10/20.PubMedCrossRef Li J, Law HK, Lau YL, Chan GC. Differential damage and recovery of human mesenchymal stem cells after exposure to chemotherapeutic agents. Br J Haematol. 2004;127(3):326–34. Epub 2004/10/20.PubMedCrossRef
32.
go back to reference Skolekova S, Matuskova M, Bohac M, Toro L, Durinikova E, Tyciakova S, et al. Cisplatin-induced mesenchymal stromal cells-mediated mechanism contributing to decreased antitumor effect in breast cancer cells. Cell communication signaling: CCS. 2016;14:4. Epub 2016/01/14.PubMedPubMedCentralCrossRef Skolekova S, Matuskova M, Bohac M, Toro L, Durinikova E, Tyciakova S, et al. Cisplatin-induced mesenchymal stromal cells-mediated mechanism contributing to decreased antitumor effect in breast cancer cells. Cell communication signaling: CCS. 2016;14:4. Epub 2016/01/14.PubMedPubMedCentralCrossRef
33.
go back to reference Rastaldo R, Vitale E, Giachino C. Dual Role of Autophagy in Regulation of Mesenchymal Stem Cell Senescence. Frontiers in cell developmental biology. 2020;8:276. Epub 2020/05/12.PubMedPubMedCentralCrossRef Rastaldo R, Vitale E, Giachino C. Dual Role of Autophagy in Regulation of Mesenchymal Stem Cell Senescence. Frontiers in cell developmental biology. 2020;8:276. Epub 2020/05/12.PubMedPubMedCentralCrossRef
34.
go back to reference Perez-Hernandez M, Arias A, Martinez-Garcia D, Perez-Tomas R, Quesada R, Soto-Cerrato V. Targeting Autophagy for Cancer Treatment and Tumor Chemosensitization. Cancers. 2019;11(10). Epub 2019/10/23. Perez-Hernandez M, Arias A, Martinez-Garcia D, Perez-Tomas R, Quesada R, Soto-Cerrato V. Targeting Autophagy for Cancer Treatment and Tumor Chemosensitization. Cancers. 2019;11(10). Epub 2019/10/23.
35.
go back to reference Autophagy. Volume 8 – Contributions. In: Hayat MA, editor. Autophagy: Cancer, Other Pathologies, Inflammation, Immunity. Infection: Academic Press; 2016. p. lxxi. Autophagy. Volume 8 – Contributions. In: Hayat MA, editor. Autophagy: Cancer, Other Pathologies, Inflammation, Immunity. Infection: Academic Press; 2016. p. lxxi.
36.
go back to reference Berger NA. Crown-like Structures in Breast Adipose Tissue from Normal Weight Women: Important Impact. Cancer Prev Res (Phila). 2017;10(4):223–5. Epub 2017/03/10.CrossRef Berger NA. Crown-like Structures in Breast Adipose Tissue from Normal Weight Women: Important Impact. Cancer Prev Res (Phila). 2017;10(4):223–5. Epub 2017/03/10.CrossRef
37.
go back to reference Faria SS, Correa LH, Heyn GS, de Sant’Ana LP, Almeida RDN, Magalhaes KG. Obesity and Breast Cancer: The Role of Crown-Like Structures in Breast Adipose Tissue in Tumor Progression, Prognosis, and Therapy. Journal of breast cancer. 2020;23(3):233–45. Epub 2020/07/01.PubMedPubMedCentralCrossRef Faria SS, Correa LH, Heyn GS, de Sant’Ana LP, Almeida RDN, Magalhaes KG. Obesity and Breast Cancer: The Role of Crown-Like Structures in Breast Adipose Tissue in Tumor Progression, Prognosis, and Therapy. Journal of breast cancer. 2020;23(3):233–45. Epub 2020/07/01.PubMedPubMedCentralCrossRef
38.
go back to reference Yang H, Zhang Q, Xu M, Wang L, Chen X, Feng Y, et al. CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis. Mol Cancer. 2020;19(1):41. Epub 2020/02/28.PubMedPubMedCentralCrossRef Yang H, Zhang Q, Xu M, Wang L, Chen X, Feng Y, et al. CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis. Mol Cancer. 2020;19(1):41. Epub 2020/02/28.PubMedPubMedCentralCrossRef
39.
go back to reference Kersten K, Coffelt SB, Hoogstraat M, Verstegen NJM, Vrijland K, Ciampricotti M, et al. Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of IL1beta in tumor-associated macrophages. Oncoimmunology. 2017;6(8):e1334744. Epub 2017/09/19.PubMedPubMedCentralCrossRef Kersten K, Coffelt SB, Hoogstraat M, Verstegen NJM, Vrijland K, Ciampricotti M, et al. Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of IL1beta in tumor-associated macrophages. Oncoimmunology. 2017;6(8):e1334744. Epub 2017/09/19.PubMedPubMedCentralCrossRef
40.
go back to reference Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000prime reports. 2014;6:13. Epub 2014/03/29. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000prime reports. 2014;6:13. Epub 2014/03/29.
41.
go back to reference Kryczek I, Wei S, Keller E, Liu R, Zou W. Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. American journal of physiology Cell physiology. 2007;292(3):C987-95. Epub 2006/09/01.PubMedCrossRef Kryczek I, Wei S, Keller E, Liu R, Zou W. Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. American journal of physiology Cell physiology. 2007;292(3):C987-95. Epub 2006/09/01.PubMedCrossRef
43.
go back to reference Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005;121(3):335–48. Epub 2005/05/11.PubMedCrossRef Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005;121(3):335–48. Epub 2005/05/11.PubMedCrossRef
44.
go back to reference Zheng H, Fu G, Dai T, Huang H. Migration of endothelial progenitor cells mediated by stromal cell-derived factor-1alpha/CXCR4 via PI3K/Akt/eNOS signal transduction pathway. J Cardiovasc Pharmacol. 2007;50(3):274–80. Epub 2007/09/20.PubMedCrossRef Zheng H, Fu G, Dai T, Huang H. Migration of endothelial progenitor cells mediated by stromal cell-derived factor-1alpha/CXCR4 via PI3K/Akt/eNOS signal transduction pathway. J Cardiovasc Pharmacol. 2007;50(3):274–80. Epub 2007/09/20.PubMedCrossRef
45.
go back to reference Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410(6824):50–6. Epub 2001/03/10.PubMedCrossRef Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410(6824):50–6. Epub 2001/03/10.PubMedCrossRef
46.
go back to reference Hojilla CV, Mohammed FF, Khokha R. Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. British journal of cancer. 2003;89(10):1817–21. Epub 2003/11/13.PubMedPubMedCentralCrossRef Hojilla CV, Mohammed FF, Khokha R. Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. British journal of cancer. 2003;89(10):1817–21. Epub 2003/11/13.PubMedPubMedCentralCrossRef
47.
48.
go back to reference Ndishabandi D, Duquette C, Billah GE, Reyes M, Duquette M, Lawler J, et al. Thrombospondin-1 Modulates Actin Filament Remodeling and Cell Motility in Mouse Mammary Tumor cells in Vitro. Discoveries (Craiova). 2014;2(4). Epub 2015/08/15. Ndishabandi D, Duquette C, Billah GE, Reyes M, Duquette M, Lawler J, et al. Thrombospondin-1 Modulates Actin Filament Remodeling and Cell Motility in Mouse Mammary Tumor cells in Vitro. Discoveries (Craiova). 2014;2(4). Epub 2015/08/15.
49.
go back to reference Yee KO, Connolly CM, Duquette M, Kazerounian S, Washington R, Lawler J. The effect of thrombospondin-1 on breast cancer metastasis. Breast cancer research treatment. 2009;114(1):85–96. Epub 2008/04/15.PubMedCrossRef Yee KO, Connolly CM, Duquette M, Kazerounian S, Washington R, Lawler J. The effect of thrombospondin-1 on breast cancer metastasis. Breast cancer research treatment. 2009;114(1):85–96. Epub 2008/04/15.PubMedCrossRef
50.
go back to reference Nassiri F, Cusimano MD, Scheithauer BW, Rotondo F, Fazio A, Yousef GM, et al. Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy. Anticancer research. 2011;31(6):2283–90. Epub 2011/07/09.PubMed Nassiri F, Cusimano MD, Scheithauer BW, Rotondo F, Fazio A, Yousef GM, et al. Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy. Anticancer research. 2011;31(6):2283–90. Epub 2011/07/09.PubMed
51.
go back to reference Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, Hall B, et al. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PloS one. 2009;4(4):e4992. Epub 2009/04/09.PubMedPubMedCentralCrossRef Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, Hall B, et al. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PloS one. 2009;4(4):e4992. Epub 2009/04/09.PubMedPubMedCentralCrossRef
52.
go back to reference Babajani A, Soltani P, Jamshidi E, Farjoo MH, Niknejad H. Recent Advances on Drug-Loaded Mesenchymal Stem Cells With Anti-neoplastic Agents for Targeted Treatment of Cancer. Front Bioeng Biotechnol. 2020;8:748. Epub 2020/08/15.PubMedPubMedCentralCrossRef Babajani A, Soltani P, Jamshidi E, Farjoo MH, Niknejad H. Recent Advances on Drug-Loaded Mesenchymal Stem Cells With Anti-neoplastic Agents for Targeted Treatment of Cancer. Front Bioeng Biotechnol. 2020;8:748. Epub 2020/08/15.PubMedPubMedCentralCrossRef
53.
go back to reference Zhao M, Sachs PC, Wang X, Dumur CI, Idowu MO, Robila V, et al. Mesenchymal stem cells in mammary adipose tissue stimulate progression of breast cancer resembling the basal-type. Cancer Biol Ther. 2012;13(9):782–92. Epub 2012/06/07.PubMedPubMedCentralCrossRef Zhao M, Sachs PC, Wang X, Dumur CI, Idowu MO, Robila V, et al. Mesenchymal stem cells in mammary adipose tissue stimulate progression of breast cancer resembling the basal-type. Cancer Biol Ther. 2012;13(9):782–92. Epub 2012/06/07.PubMedPubMedCentralCrossRef
54.
go back to reference Kuol N, Stojanovska L, Apostolopoulos V, Nurgali K. Role of the nervous system in cancer metastasis. Journal of experimental clinical cancer research: CR. 2018;37(1):5. Epub 2018/01/18.PubMedPubMedCentralCrossRef Kuol N, Stojanovska L, Apostolopoulos V, Nurgali K. Role of the nervous system in cancer metastasis. Journal of experimental clinical cancer research: CR. 2018;37(1):5. Epub 2018/01/18.PubMedPubMedCentralCrossRef
55.
go back to reference Sloan EK, Priceman SJ, Cox BF, Yu S, Pimentel MA, Tangkanangnukul V, et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer research. 2010;70(18):7042–52. Epub 2010/09/09.PubMedPubMedCentralCrossRef Sloan EK, Priceman SJ, Cox BF, Yu S, Pimentel MA, Tangkanangnukul V, et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer research. 2010;70(18):7042–52. Epub 2010/09/09.PubMedPubMedCentralCrossRef
56.
go back to reference Huang D, Su S, Cui X, Shen X, Zeng Y, Wu W, et al. Nerve fibers in breast cancer tissues indicate aggressive tumor progression. Medicine. 2014;93(27):e172. Epub 2014/12/17.PubMedPubMedCentralCrossRef Huang D, Su S, Cui X, Shen X, Zeng Y, Wu W, et al. Nerve fibers in breast cancer tissues indicate aggressive tumor progression. Medicine. 2014;93(27):e172. Epub 2014/12/17.PubMedPubMedCentralCrossRef
Metadata
Title
Chemotherapy-triggered changes in stromal compartment drive tumor invasiveness and progression of breast cancer
Authors
Jana Plava
Monika Burikova
Marina Cihova
Lenka Trnkova
Bozena Smolkova
Pavel Babal
Lucia Krivosikova
Pavol Janega
Lucia Rojikova
Slavka Drahosova
Martin Bohac
Lubos Danisovic
Lucia Kucerova
Svetlana Miklikova
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2021
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-021-02087-2

Other articles of this Issue 1/2021

Journal of Experimental & Clinical Cancer Research 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine